Ergomed PLC (AIM:ERGO, ETR:2EM) said recent strong momentum has continued with good performances in the first half at its clinical services (CRO) and pharmacovigilance (PV) arms.
Revenues overall rose by almost 25% to £69.9mln in the half year to end June 2022, led by a 26% rise in CRO and 23% in PV.
Ergomed added that orders had also stayed healthy, with the total at the end of the half year at £284.5mln - up 19% from six months earlier.
In February, it acquired ADAMAS, a quality assurance specialist, with integration going well said the statement.
Miroslav Reljanović, executive chairman, added: "Ergomed has delivered further significant strategic progress in H1 2022.
“Our strong organic growth has continued, with expansion into new territories and further strengthening of the company's board and leadership team.
“The board expects to deliver the anticipated trading growth and financial results for the full year in line with current market expectations and we look forward with confidence to the rest of this year and beyond."
Cash at the end of the period was £12mln against £24.6mln a year earlier but this was after £24.2mln paid for ADAMAS, said the company, and highlighted the strong inflows in the first half.